With $100M, Camp4 plans to bring two ‘regRNA’ drugs to clinical trials

One year after it unveiled $45 million in Series A funding, a Cambridge startup working to harness what it calls "regulatory RNAs" has brought in another $100 million in a final push to get its two lead programs into clinical trials.